Literature DB >> 27087442

APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.

Meng Zhou, Tianwen Huang, Nicole Collins, Jing Zhang, Hui Shen, Xiaoman Dai, Naian Xiao, Xilin Wu, Zhen Wei, Jason York, Lanyan Lin, Yuangui Zhu, Mary Jo LaDu, Xiaochun Chen1.   

Abstract

APOE4 is the greatest genetic risk factor for Alzheimer's disease (AD), particularly associated with increased levels of amyloid-β (Aβ) and amyloid deposition. However, it remains unclear whether APOE4 is associated with greater tau phosphorylation and neurofibrillary tangle formation, a hallmark of AD leading to structural disruption of the neuronal cytoskeleton. The current study used 3 and 7 month old EFAD mice, which express human APOE and over-express specifically human Aβ42 via 5 familial-AD (FAD) mutations, to investigate APOE genotype-specific effects on site-specific tau phosphorylation. The results reveal that AD-like site-specific tau phosphorylation was increased in E4FAD mice, accompanied by disrupted cortical neuronal morphology, compared to E3FAD mice. Further analysis demonstrated that the levels of CDK5, its regulatory subunits (p35 and p25) and calpain (including calpain1 and calpain2), but not GSK3β, were significantly increased in E4FAD mice compared to E3FAD mice. These results suggest that the APOE4 genotype contributes to increased site-specific tau phosphorylation via activation of the calpain-CDK5 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27087442     DOI: 10.2174/1567205013666160415154550

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  13 in total

Review 1.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

Review 2.  Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Authors:  Yang Shi; David M Holtzman
Journal:  Nat Rev Immunol       Date:  2018-12       Impact factor: 53.106

3.  The influence of anesthetics on substantia nigra tyrosine hydroxylase expression and tau phosphorylation in the hypoxic-ischemic near-term lamb.

Authors:  Melinda Barkhuizen; Fleur J P van Dijck; Reint K Jellema; Ruth Gussenhoven; Imke Engelbertink; Ralph van Mechelen; Jack P M Cleutjens; Matthias Seehase; Harry W M Steinbusch; Luc J Zimmermann; A W Danilo Gavilanes; Boris W Kramer
Journal:  Pediatr Res       Date:  2018-05-09       Impact factor: 3.756

Review 4.  The role of APOE in transgenic mouse models of AD.

Authors:  Deebika Balu; Aimee James Karstens; Efstathia Loukenas; Juan Maldonado Weng; Jason M York; Ana Carolina Valencia-Olvera; Mary Jo LaDu
Journal:  Neurosci Lett       Date:  2019-05-28       Impact factor: 3.046

Review 5.  EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease.

Authors:  Leon M Tai; Deebika Balu; Evangelina Avila-Munoz; Laila Abdullah; Riya Thomas; Nicole Collins; Ana Carolina Valencia-Olvera; Mary Jo LaDu
Journal:  J Lipid Res       Date:  2017-04-07       Impact factor: 5.922

6.  Chronic diabetic states worsen Alzheimer neuropathology and cognitive deficits accompanying disruption of calcium signaling in leptin-deficient APP/PS1 mice.

Authors:  Shuai Zhang; Rui Chai; Ying-Ying Yang; Shi-Qi Guo; Shan Wang; Tian Guo; Shuang-Feng Xu; Yan-Hui Zhang; Zhan-You Wang; Chuang Guo
Journal:  Oncotarget       Date:  2017-07-04

7.  In vivo induction of membrane damage by β-amyloid peptide oligomers.

Authors:  Carl Julien; Colson Tomberlin; Christine M Roberts; Aumbreen Akram; Gretchen H Stein; Michael A Silverman; Christopher D Link
Journal:  Acta Neuropathol Commun       Date:  2018-11-29       Impact factor: 7.801

Review 8.  ApoE4: an emerging therapeutic target for Alzheimer's disease.

Authors:  Mirna Safieh; Amos D Korczyn; Daniel M Michaelson
Journal:  BMC Med       Date:  2019-03-20       Impact factor: 8.775

9.  Harnessing the paradoxical phenotypes of APOE ɛ2 and APOE ɛ4 to identify genetic modifiers in Alzheimer's disease.

Authors:  Young Won Kim; Ismael Al-Ramahi; Amanda Koire; Stephen J Wilson; Daniel M Konecki; Samantha Mota; Shirin Soleimani; Juan Botas; Olivier Lichtarge
Journal:  Alzheimers Dement       Date:  2020-12-07       Impact factor: 21.566

10.  Influence of APOE and RNF219 on Behavioral and Cognitive Features of Female Patients Affected by Mild Cognitive Impairment or Alzheimer's Disease.

Authors:  Alessandra Mosca; Samantha Sperduti; Viorela Pop; Domenico Ciavardelli; Alberto Granzotto; Miriam Punzi; Liborio Stuppia; Valentina Gatta; Francesca Assogna; Nerisa Banaj; Fabrizio Piras; Federica Piras; Carlo Caltagirone; Gianfranco Spalletta; Stefano L Sensi
Journal:  Front Aging Neurosci       Date:  2018-04-13       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.